Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum toxin efficacy factors in upper-extremity dystonic tremor syndrome
NL-OMON60104Phase 4Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of botulinum toxin type A in dystonic tremor, sponsored by Radboud University Medical Center. Primary endpoint: Association between tremor characteristics and botulinum toxin efficacy. Started Dec 2024; status: active, not recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
dystonic tremor
Beyond the preview
Go deeper on NL-OMON60104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60104.